{"id":205958,"url":"https://lda.senate.gov/api/v1/clients/205958/?format=json","client_id":24,"name":"ATEA PHARMACEUTICALS","general_description":"Drug development and COVID 19 issues involving FDA, DOD, HHS, and OWS","client_government_entity":false,"client_self_select":null,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-06-12","registrant":{"id":401105698,"url":"https://lda.senate.gov/api/v1/registrants/401105698/?format=json","house_registrant_id":null,"name":"BURT ROSEN STRATEGIES","description":"Government Affairs Strategies and Advice","address_1":"2501 Pennsylvania Ave. NW #3A","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20037","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BURT ROSEN","contact_telephone":"+1 202-494-0437","dt_updated":"2025-05-21T11:43:11.385396-04:00"}}